Related Experiment Video
Updated: Jan 23, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth
Josephine S Kim1, Jane Turbov2, Rebecca Rosales2
1Division of Gynecologic Oncology, NorthShore University HealthSystem, 2650 Ridge Avenue, Suite 1507, Walgreen Building, Evanston, IL 60201, USA; Section of Gynecologic Oncology, The University of Chicago Medicine, 5841 S. Maryland Avenue, MC 2050, Chicago, IL 60637, USA.
Objective:
Recent data show that simvastatin (SIM) and metformin (MET) have anti-proliferative effects in endometrial cancer cells. The combination (MET+SIM) inhibits tumor growth and metastasis in prostate cancer cells which possess similar molecular alterations to many early endometrial cancers. We tested the hypothesis that the anti-proliferative effects of MET+SIM in endometrial cancer cells would be greater than the effects of each agent alone.
Methods:
RL95-2, HEC1B, and Ishikawa endometrial cancer cell lines were treated with MET and/or SIM. Growth inhibition was measured by MTS cell proliferation assays. Apoptosis was evaluated by caspase-3, Annexin V, and TUNEL assays and by apoptosis markers (BAX, Bcl-2, Bim) using western blot. Bim was silenced using Bim siRNA to confirm this apoptotic pathway. Treatment effects on the mTOR pathway were investigated by western blot using antibodies to phosphorylated (phospho)-AMPK and phospho-S6.
Results:
MET+SIM synergistically inhibited growth in all three cell lines. The combination induced apoptosis as measured by TUNEL, Annexin V, and caspase-3 assays. Bim siRNA transfection abrogated this effect-silencing Bim in MET+SIM-treated RL95-2 cells rescued cell viability in MTS assays and reduced caspase-3 activity compared with control siRNA-transfected cells. Combination treatment upregulated phosphorylated AMPK and downregulated downstream phosphorylated S6, suggesting mTOR inhibition as a mechanism for these anti-proliferative effects.
Conclusions:
MET+SIM treatment synergistically inhibits endometrial cancer cell viability. This may be mediated by apoptosis and mTOR pathway inhibition. Our results provide preclinical evidence that the combination of these well-tolerated drugs may warrant further clinical investigation for endometrial cancer treatment.
Insights
The combination of simvastatin (SIM) and metformin (MET) synergistically inhibits endometrial cancer cell growth. This effect is mediated by apoptosis and mTOR pathway inhibition, suggesting potential for clinical investigation.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Simvastatin (SIM) and metformin (MET) exhibit anti-proliferative effects on cancer cells.
- The MET+SIM combination shows promise in prostate cancer models with similarities to early endometrial cancers.
Purpose of the Study:
- To evaluate the synergistic anti-proliferative effects of MET+SIM in endometrial cancer cells.
- To investigate the underlying mechanisms, including apoptosis and mTOR pathway modulation.
Main Methods:
- Endometrial cancer cell lines (RL95-2, HEC1B, Ishikawa) were treated with MET and/or SIM.
- Cell proliferation was assessed using MTS assays.
- Apoptosis was evaluated via caspase-3, Annexin V, and TUNEL assays, alongside western blotting for apoptosis markers (BAX, Bcl-2, Bim).
- mTOR pathway activity was analyzed by western blotting for phospho-AMPK and phospho-S6.
Main Results:
- MET+SIM demonstrated synergistic growth inhibition across all tested cell lines.
- The combination treatment significantly induced apoptosis, confirmed by multiple assays.
- Silencing Bim abrogated the anti-proliferative and pro-apoptotic effects of MET+SIM.
- Combination therapy led to upregulated phospho-AMPK and downregulated phospho-S6, indicating mTOR inhibition.
Conclusions:
- MET+SIM synergistically inhibits endometrial cancer cell viability through apoptosis and mTOR pathway interference.
- These findings provide preclinical support for investigating MET+SIM as a potential endometrial cancer therapy.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Related Concept Videos
Feedback Inhibition
Enzyme Inhibition
Primary and Secondary Growth in Roots and Shoots
Cells Coordinate Growth and Proliferation
Population Growth
Meristems and Plant Growth